Company logo

BNGO - Bionano Genomics, Inc.

NASDAQ -> Healthcare -> Diagnostics & Research
San Diego, United States
Type: Equity

BNGO price evolution
BNGO
(in millions $) 30 Jun 2024 31 Mar 2024 31 Dec 2023 30 Sep 2023
Current assets
Cash $21.43 $16.16 $18.35 $34.97
Short term investments $8.52 $37.01 $83.94 $29.01
Net receivables $6.25 $8.31 $9.32 $8.67
Inventory $19.48 $19.59 $22.89 $26.43
Total current assets $60.57 $85.61 $140.12 $104.54
Long term investments $0.4
Property, plant & equipment $32.49 $33.6 $32.48 $30.99
Goodwill & intangible assets $30.02 $31.73 $33.97 $35.77
Total noncurrent assets $68.8 $72.38 $74.29 $77.37
Total investments $8.92 $37.01 $83.94 $29.01
Total assets $129.36 $158 $214.4 $181.9
Current liabilities
Accounts payable $8.73 $9.84 $10.38 $15.37
Deferred revenue $1.42 $1.17 $0.94 $0.96
Short long term debt $21.76 $31.54 $72.24 $2.46
Total current liabilities $37.17 $58.51 $100.03 $40.19
Long term debt $5.81 $6.33 $7.17 $7.68
Total noncurrent liabilities $11.85 $16.72 $18.22 $22.71
Total debt $27.57 $37.87 $79.41 $10.14
Total liabilities $49.03 $75.22 $118.25 $62.91
Shareholders' equity
Retained earnings -$628.85 -$612.63 -$581.21 -$537.32
Other shareholder equity -$0 -$0.02 $0.02 -$0.09
Total shareholder equity $80.34 $82.77 $96.16 $119
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $18.35 $5.49 $24.57 $38.45
Short term investments $83.94 $108.09 $226.04
Net receivables $9.32 $7.5 $4.93 $2.78
Inventory $22.89 $29.76 $12.39 $3.32
Total current assets $140.12 $157.3 $272.41 $46.79
Long term investments
Property, plant & equipment $32.48 $28.96 $20.93 $4.91
Goodwill & intangible assets $33.97 $118.43 $83 $8.65
Total noncurrent assets $74.29 $150.2 $104.69 $13.66
Total investments $83.94 $108.09 $226.04
Total assets $214.4 $307.5 $377.1 $60.45
Current liabilities
Accounts payable $10.38 $12.53 $9.7 $2.93
Deferred revenue $0.94 $0.87 $0.68 $0.42
Short long term debt $72.24 $2.54 $1.77
Total current liabilities $100.03 $35.88 $21.84 $8.94
Long term debt $7.17 $3.62 $8.93 $16.33
Total noncurrent liabilities $18.22 $22.22 $18.14 $16.42
Total debt $79.41 $11.67 $10.7 $16.33
Total liabilities $118.25 $58.1 $39.98 $25.37
Shareholders' equity
Retained earnings -$581.21 -$348.71 -$216.12 -$143.68
Other shareholder equity $0.02 -$1.12 -$0.54 $0
Total shareholder equity $96.16 $249.4 $337.12 $35.08
(in millions $) 30 Jun 2024 31 Mar 2024 31 Dec 2023 30 Sep 2023
Revenue
Total revenue $7.77 $8.77 $10.72 $9.32
Cost of revenue $5.19 $5.95 $8.28 $6.57
Gross Profit $2.58 $2.82 $2.44 $2.75
Operating activities
Research & development $6.83 $9.78 $11.7 $13.79
Selling, general & administrative $11.56 $19.54 $15.69 $24.9
Total operating expenses $19.6 $33.95 $23.94 $115.96
Operating income -$17.02 -$31.12 -$21.5 -$113.21
Income from continuing operations
EBIT -$16.2 -$31.32 -$39.03 -$112.46
Income tax expense $0.03 -$0.02 -$0.04 $0.04
Interest expense $0.12 $4.9 $0.07
Net income
Net income -$16.22 -$31.42 -$43.89 -$112.57
Income (for common shares) -$16.22 -$31.42 -$43.89 -$112.57
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $36.12 $27.8 $17.98 $8.5
Cost of revenue $26.55 $21.86 $14.11 $5.73
Gross Profit $9.57 $5.95 $3.87 $2.77
Operating activities
Research & development $54.03 $49.05 $22.48 $10.26
Selling, general & administrative $93.5 $88.6 $58.49 $31.07
Total operating expenses $221.36 $137.87 $81.03 $41.33
Operating income -$211.8 -$131.92 -$77.16 -$38.56
Income from continuing operations
EBIT -$227.31 -$130.41 -$77.22 -$38.56
Income tax expense $0.06 $1.88 -$5.72 $0.03
Interest expense $5.12 $0.3 $0.93 $2.52
Net income
Net income -$232.49 -$132.6 -$72.44 -$41.11
Income (for common shares) -$232.49 -$132.6 -$72.44 -$41.11
(in millions $) 30 Jun 2024 31 Mar 2024 31 Dec 2023 30 Sep 2023
Net income -$16.22 -$31.42 -$43.89 -$112.57
Operating activities
Depreciation $3.13 $3.08 $3.67 $3.69
Business acquisitions & disposals
Stock-based compensation $2.58 $3.02 $3.37 $3.99
Total cash flows from operations -$20.98 -$28.13 -$29.78 -$26.29
Investing activities
Capital expenditures -$0.08 -$0.03 -$0.74 -$0.07
Investments $28.71 $47.61 -$54.63 $33.5
Total cash flows from investing $28.63 $47.59 -$55.37 $33.43
Financing activities
Dividends paid
Sale and purchase of stock $11.19 $15.06 $11.02 $12.6
Net borrowings -$11.73 -$36.68 $66.47 -$0.01
Total cash flows from financing -$1.98 -$21.62 $68.48 $12.59
Effect of exchange rate -$0 -$0.03 $0.05 -$0.01
Change in cash and equivalents $5.67 -$2.19 -$16.62 $19.71
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$232.49 -$132.6 -$72.44 -$41.11
Operating activities
Depreciation $13.97 $10.1 $4.04 $1.48
Business acquisitions & disposals $0.1 -$30.65 -$49.09 -$2.45
Stock-based compensation $15.18 $22.42 $9.72 $1.55
Total cash flows from operations -$125.18 -$124.82 -$71.93 -$38.31
Investing activities
Capital expenditures -$1.69 -$3.17 -$2.07
Investments $25.75 $116.69 -$226.91
Total cash flows from investing $24.16 $82.77 -$278.06 -$2.45
Financing activities
Dividends paid
Sale and purchase of stock $56.38 $23.04 $351.12 $66.63
Net borrowings $66.43 -$0.04 -$15.01 -$4.72
Total cash flows from financing $113.81 $23.01 $336.11 $61.9
Effect of exchange rate $0.07 -$0.04
Change in cash and equivalents $12.86 -$19.08 -$13.88 $21.14
Fundamentals
Market cap $32.56M
Enterprise value $38.69M
Shares outstanding 70.78M
Revenue $36.58M
EBITDA -$185.43M
EBIT -$199.00M
Net Income -$204.10M
Revenue Q/Q -10.29%
Revenue Y/Y 16.08%
P/E ratio -0.16
EV/Sales 1.06
EV/EBITDA -0.21
EV/EBIT -0.19
P/S ratio 0.89
P/B ratio 0.41
Book/Share 1.14
Cash/Share 0.30
EPS -$2.88
ROA -119.42%
ROE -215.83%
Debt/Equity 1.23
Net debt/EBITDA -0.15
Current ratio 1.63
Quick ratio 1.11